Investing Profile

Florian Müllershausen

InvestorVC
Managing Director at Novartis Venture Fund
nvfund.comBasel, Switzerland
Photo of Florian Müllershausen, Managing Director at Novartis Venture Fund

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
Novartis Venture Fund Managing Director
$5.0M - $10.0M
$7.5M
13
$750M
CompanyStageDateRound SizeTotal Raised
Artios Pharma
Series DNov 2025$120M
Series CJul 2021$150M
Series BAug 2018$83M
$380M
Co-investors: Nikola Trbovic (Pfizer Venture Investments), Barbara Dalton (Pfizer Venture Investments), Jake Simson (RA Capital), Hakan Goker (M Ventures (Merck)), Raphael Wisniewski (Andera Partners)
NRG Therapeutics
Series BSep 2025$68M
$86M
Co-investors: Jonathan Tobin (Brandon Capital Partners), Laurence Barker (SV Health Investors)
FoRx Therapeutics
Series AJun 2025$49M
SeedApr 2020$11M
$60M
Co-investors: Denis Patrick (Pfizer Venture Investments), Therese Liechtenstein (M Ventures (Merck)), Vincent Ossipow (Omega Funds)
Rhygaze
Series AJan 2025$86M
SeedJul 2024$11M
$97M
Co-investors: Daniela Couto (BGV (BioGeneration Ventures))
Citryll
Series BDec 2024$90M
$110M
Co-investors: Edward Van Wezel (BGV (BioGeneration Ventures)), Geert-Jan Mulder (Forbion), Isabelle de Cremoux (Seventure Partners)
LOQUS23 THERAPEUTICS
Series AOct 2024$46M
SeedNov 2021$9M
$55M
Co-investors: Rogier Rooswinkel (Forbion)
Amphista Therapeutics
Series BMar 2021$53M
$61M
Co-investors: Satish Jindal (Advent Life Sciences), Raj Parekh (Advent Life Sciences), Rogier Rooswinkel (Forbion)
Anaveon
Series AFeb 2019$35M
$160M
Co-investors: Ohad Hammer (Pontifax Venture Capital), Jasper Bos (Forbion), Denis Patrick (Pfizer Venture Investments)
Ruhr University Bochum Dr. rer. nat. (PhD)
Freie Universität Berlin Diploma (eq. to MSc